Increased frequency of NGF in sera of rheumatoid arthritis and systemic lupus erythematosus patients

Dicou, Eleni; Masson, Charles; Jabbour, W.; Nerrière, V.

doi:10.1097/00001756-199312000-00036

Cited by 45 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chaldakov and coworkers have hypothesized that a reduction in NT production could be implicated in the pathogenesis of obesity and related comorbidities, and reported that hyponeurotrophinemia was present in a group of patients with the MetSyn or cardiovascular disease and not in healthy subjects (10,(26)(27)(28). However, such a proposal is not in agreement with the relationship described between NTs and other inflammatory diseases (20,21). In contrast to these previous studies, our results show an increase in NGF plasma levels in patients with obesity or MetSyn.…”

Section: Discussionmentioning

confidence: 96%

“…Several studies over the last decade have implicated NTs in the pathogenesis of various inflammatory diseases (20,21). The expression and production in immune cells of one or more NTs together with NT receptors have been described (33,34).…”

Section: Discussionmentioning

confidence: 99%

“…Several authors have reported high plasma levels of NGF, BDNF, and NT3 in patients with rheumatoid arthritis, systemic lupus erythaematosis, allergic disease, or asthma (20,21). Higher plasma levels of these NTs have also been described in type 1 diabetic patients (22).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women

et al. 2007

View full text Add to dashboard Cite

Objective: Neurotrophins (NTs) could be involved in the development and progression of inflammatory and immune diseases. Because obesity and the metabolic syndrome (MetSyn) are related to a lowgrade systemic inflammation, plasma NT levels (neurotrophinemia) could play an important role in the ethiopathogenic mechanisms underlying these metabolic derangements. This is the first study evaluating the plasma NT levels in a group of women with obesity and MetSyn, and also the adipose tissue nerve growth factor (NGF) expression in a small group of them. Methods: Included were 146 adult women with different degrees of adiposity, with or without MetSyn. Plasma NT levels were measured. NGF expression was analyzed in s.c. adipose tissue of a subgroup of morbidly obese and normal-weight females. Results: NGF plasma levels were 1.4-fold higher in overweight and obese subjects. Plasma NGF was, however, lower in a group of morbidly obese subjects than in overweight or obesity, but it remained elevated relative to the normal-weight group. Plasma NGF was significantly correlated with body mass index (BMI), percentage body fat, and waist circumference in non-morbidly obese subjects. NGF was positively related to inflammatory markers. NT3 and brain-derived neurotrophin factor seem to be more related to lipid profile than to BMI, adipose tissue distribution, or peripheral inflammatory markers. Subjects with type 2 diabetes, abdominal fat distribution, or the MetSyn showed significantly higher levels of NGF. The MetSyn was the only independent predictor of the variability observed in the NGF plasma values. Conclusion: NGF is upregulated in obesity, type 2 diabetes, and the MetSyn. Whether this NT may contribute to inflammation and the metabolic derangements associated with body weight gain remains to be elucidated.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In rodents and primates, no denervation or changes in sensory or sympathetic innervation density or structural toxicities in the nervous system have been reported (28). Moreover, the presence of natural anti-NGF autoantibodies in adult humans is not associated with neurologic deficits (53)(54)(55)(56)(57)(58). Nevertheless, the effects of long-term neutralization of NGF must to be carefully considered.…”

Section: Discussionmentioning

confidence: 99%

A Virus-Like Particle-Based Anti-Nerve Growth Factor Vaccine Reduces Inflammatory Hyperalgesia: Potential Long-Term Therapy for Chronic Pain

Röhn¹,

Ralvenius

Paul

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

Chronic pain resulting from inflammatory and neuropathic disorders causes considerable economic and social burden. For a substantial proportion of patients, conventional drug treatments do not provide adequate pain relief. Consequently, novel approaches to pain management, involving alternative targets and new therapeutic modalities compatible with chronic use, are being sought. Nerve growth factor (NGF) is a major mediator of chronic pain. Clinical testing of NGF antagonists is ongoing, and clinical proof of concept has been established with a neutralizing mAb. Active immunization, with the goal of inducing therapeutically effective neutralizing autoreactive Abs, is recognized as a potential treatment option for chronic diseases. We have sought to determine if such a strategy could be applied to chronic pain by targeting NGF with a virus-like particle (VLP)-based vaccine. A vaccine comprising recombinant murine NGF conjugated to VLPs from the bacteriophage Qβ (NGFQβ) was produced. Immunization of mice with NGFQβ induced anti-NGF–specific IgG Abs capable of neutralizing NGF. Titers could be sustained over 1 y by periodic immunization but declined in the absence of boosting. Vaccination with NGFQβ substantially reduced hyperalgesia in collagen-induced arthritis or postinjection of zymosan A, two models of inflammatory pain. Long-term NGFQβ immunization did not change sensory or sympathetic innervation patterns or induce cholinergic deficits in the forebrain, nor did it interfere with blood-brain barrier integrity. Thus, autovaccination targeting NGF using a VLP-based approach may represent a novel modality for the treatment of chronic pain.

show abstract

“…At present, data regarding NGF levels in the synovial fluid of chronic autoimmune diseases seem to be equivocal. Some authors have found increased levels of NGF in SF and sera from RA, systemic lupus erythematosus (SLE), and seronegative spondyloarthropy (SpA) patients (27,28). In another study, serum levels of NGF and brain-derived neurotrophic factor (BDNF) were measured before and after therapy in RA patients treated with anti-TNF agents.…”

Section: Discussionmentioning

confidence: 99%

The regulatory role of nerve growth factor and its receptor system in fibroblast‐like synovial cells

Raychaudhuri¹,

Raychaudhuri

2009

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

Upregulation of NGF/TrkA in proinflammatory cytokine-activated FLS, the mitogenic effect of NGF on FLS, and the increased NGF level in SF of inflammatory arthritis suggest that there is cross-talk between NGF/NGF-R and FLS. These results also suggest that dysregulated production of NGF may lead to synovial cell proliferation and thus could influence the inflammatory and proliferative cascades of inflammatory arthritis.

show abstract

Increased frequency of NGF in sera of rheumatoid arthritis and systemic lupus erythematosus patients

Cited by 45 publications

References 0 publications

Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women

Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women

A Virus-Like Particle-Based Anti-Nerve Growth Factor Vaccine Reduces Inflammatory Hyperalgesia: Potential Long-Term Therapy for Chronic Pain

The regulatory role of nerve growth factor and its receptor system in fibroblast‐like synovial cells

Contact Info

Product

Resources

About